A seller promising that the price will not move as your dose climbs is making the single most valuable commitment available in this category. The obvious expectation is that such a promise costs money — that a flat rate is priced to absorb the escalation, and therefore starts higher. Across this roster it does not — which makes it one of the few places where better disclosure and a lower bill arrive together, rather than trading off as they do in is a GLP-1 worth what it costs.
The three groups
267 injected semaglutide rows say nothing about dose at all. 137 state that the rate holds at every dose. 28 state that it rises. The groups are wildly uneven, which is itself the first finding: the commonest position in this market is silence, counted in nobody says what happens at a higher dose.
What each group charges
Sellers making the flat promise have a median billed figure of $169, with a middle half running $129 to $199. Sellers saying nothing sit at $179, from $149 to $219. Those stating the price rises sit at $155.
The flat-rate group sits below the other two at the median and across most of the distribution. A buyer choosing that disclosure is not paying extra for it.
Why the promise is worth more than the median gap
The difference between the groups is modest at the median. The difference the promise makes to a buyer is not, because a rate that holds converts a monthly figure into an annual one that can actually be multiplied. Everything this site calculates about a year depends on knowing whether the figure survives month four.
Against a seller that says nothing, a buyer is holding a number with an unknown attached and no way to price it. The full arithmetic on what that unknown does to a total is in what a GLP-1 actually costs, and the other gap between advertised and billed figures is counted in the gap between what is shown and what is billed. Roster read September 2026.